The FDA has approved an injection in combination with an established oral therapy for the treatment of acute promyelocytic leukemia. READ MORE
The FDA has approved an injection in combination with an established oral therapy for the treatment of acute promyelocytic leukemia.
A recent study found that while treatment outcomes for a CLL therapy are comparable in clinical trials and the real-world setting, adverse events are increased in the latter.
Risk algorithms for pediatric patients with acute lymphoblastic leukemia should incorporate genetics with minimal residual disease for optimal accuracy.
Patients with acute myeloid leukemia and good nutritional status have greater 12-month survival rates and shorter hospital stays than patients who are undernourished, according to results of a study.
Research in Review
A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma.
Recent research in the Journal of Clinical Oncology examined outcomes for patients with myeloid malignancies who had vitamin D deficiency before undergoing allogeneic stem cell transplantation.
Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia and a specific mutation.
Single-agent immunotherapy in patients with a subtype of diffuse large B-cell lymphoma provides more clinical benefit than conventional therapy.
The FDA just announced that it will allow marketing of the first agency-authorized test for use with flow cytometry in order to help in the detection of several leukemias and lymphomas.
Adolescent and young adult survivors of Hodgkin lymphoma may not be receiving the recommended post-treatment care.